Oral pill for immune thrombocytopenia after first treatment fails
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a confirmed diagnosis of primary ITP (not caused by another condition)
- You have had at least one standard first treatment for ITP and it worked for a while
- Your ITP has come back, you no longer respond to treatment, or you are dependent on steroids
- You have not had your spleen removed and have not received advanced therapies like rituximab or fostamatinib
- You do not have another bleeding disorder, cancer in the last 5 years (except non-melanoma skin cancer), or a history of organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called zanubrutinib to find the best dose for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, leading to low counts and bleeding risk. It may offer a new treatment option for those who haven't had any prior therapy.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.